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ABSTRACT
Introduction: Diagnosis of inflammatory bowel
disease (IBD) in primary healthcare is challenging and
often associated with a considerable diagnostic delay.
This delay is associated with worse disease
progression and outcomes. Although testing for faecal
calprotectin is a useful screening tool to identify
patients who need endoscopy for IBD, the widespread
use may not be appropriate due to the low prevalence
of patients with IBD among all patients attending a
general practitioner (GP) with gastrointestinal
symptoms. To increase the appropriate
application of the faecal calprotectin test,
an 8-item questionnaire, the CalproQuest, has been
developed to increase pretest probability for a positive
test result.
Methods and analysis: This is a prospective
diagnostic trial. The study consists of two independent
and consecutive parts A and B, conducted by
gastroenterologists (A) and GPs (B), respectively.
Patients included in part A are referred to the
gastroenterologist for any endoscopic evaluation.
Patients included in part B present at their GP because
of ongoing unspecific gastrointestinal symptoms
(abdominal pain, bloating, stool irregularities,
diarrhoea) for at least 2 weeks. CalproQuest consists of
four main and four secondary questions specific for
IBD; it is considered positive if ≥2 main criteria are
answered positively or one main criterion and two
secondary criteria are answered positively. In part A,
the sensitivity and specificity of CalproQuest for stool
calprotectin levels ≥50 μg/g faeces and for positive
IBD diagnosis will be investigated. In part B, the
feasibility of CalproQuest in daily primary healthcare
practice will be assessed.
Ethics and dissemination: The study protocol was
approved by the Ethics Committee of the Kanton
Zurich (reference KEK-ZH-number 2013-0516). The
results will be published in a peer-reviewed journal and
shared with the worldwide medical community.
Trial registration number: ISRCTN66310845.
INTRODUCTION
IBD versus IBS
Crohn’s disease (CD), ulcerative colitis (UC)
and indeterminate colitis represent the three
subtypes of inﬂammatory bowel disease
(IBD).1 The estimated prevalence rates of
IBD in Swiss population are about 205.6
cases per 100 000.2
Meanwhile, the prevalence of irritable
bowel syndrome (IBS) in Europe and North
America is estimated to be 10–15%.3
Physicians are often faced with the diagnos-
tic challenge of differentiating patients with
IBD from those with functional disorders such
as IBS. Indeed, symptoms similar to IBS are
frequently reported in patients before IBD is
diagnosed.4 The gold diagnostic standard is
endoscopy; however, not every patient with the
symptoms overlapping with those of IBS can
be investigated by the invasive endoscopic
examination. Therefore, many different, non-
invasive markers have been investigated.
Several studies have shown that faecal calpro-
tectin accurately reﬂects intestinal inﬂamma-
tion in patients with known IBD.5
It has also been shown to consistently dif-
ferentiate IBD from IBS due to its excellent
negative predictive value. It can therefore be
used ruling out IBD in undiagnosed and
symptomatic patients.6
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Calprotectin, a S100 protein
Calprotectin is a complex of two calcium-binding pro-
teins that belong to the S100 protein family.7 It is abun-
dant in the cytosolic fraction of neutrophils. High levels
of calprotectin have been found in extracellular ﬂuid
during various inﬂammatory conditions, such as rheuma-
toid arthritis, cystic ﬁbrosis and abscesses. Calprotectin
released from neutrophils has growth-inhibitory and
apoptosis-inducing activities against various cell types
including tumour cells and normal ﬁbroblasts.7 This sug-
gests that calprotectin has regulatory activities during
inﬂammatory processes through its effect on the survival
or growth states of cells participating in the inﬂammatory
reaction. Furthermore, calprotectin inhibits microbial
growth through competition for zinc.8
Calprotectin has been shown to be stable in faeces
during storage for 7 days at room temperature, which is
very important for its value in evaluating mucosal wall
inﬂammation.9
Stool calprotectin levels as marker of intestinal
inflammation
Data correlated to faecal calprotectin showed a sensitivity
and speciﬁcity of calprotectin (using a cut-off value of
10 mg/L) for organic disease of 89% and 79%, respect-
ively.10 Studies using a cut-off value of 50μg/g showed a
sensitivity and speciﬁcity of 86.8% and 95.7%11 and 83%
and 100%12 discriminating IBD versus IBS. Faecal cal-
protectin levels correlate signiﬁcantly with histological
and endoscopic assessment of disease activity in UC13–15
as well as with faecal α-1-antitrypsin levels and faecal
excretion of 111 indium-labelled white cells count in
patients with CD.16 17 Previous studies showed that stool
calprotectin levels correlate well with endoscopic indices
in UC and in CD.18–20
Diagnostic delay in IBD is predictive for worse disease
progression and outcomes
Difﬁculties in differentiation of early IBD from IBS,
especially in a primary healthcare setting, are leading to
a considerable diagnostic delay in IBD.1 This delay has
an important clinical impact, as there is increasing evi-
dence demonstrating that treatment success is increased
in early disease.21–24 Vavricka et al1 suggest that diagnos-
tic delay is subdivided into two intervals, where interval
one is deﬁned as the time from ﬁrst symptoms to phys-
ician visit, and interval two as the time from ﬁrst phys-
ician visit to IBD diagnosis. The study by Vavricka et al1
estimates that 25% of all patients with CD and UC
experienced more than 24 and 12 months, respectively,
from ﬁrst onset of symptoms until an accurate IBD diag-
nosis. Most importantly, Schoepfer et al25 recently
showed that the length of diagnostic delay is correlated
with an increased risk of bowel stenosis and CD-related
intestinal surgery, concluding that efforts should be
undertaken to shorten diagnostic delay.
Testing calprotectin in Switzerland
Most analytical laboratories in Switzerland offer calpro-
tectin testing, which is reimbursed by health insurances.
Faecal calprotectin testing in primary healthcare versus
tertiary healthcare
Although calprotectin tests are easily accessible and
reimbursed in Switzerland, this diagnostic test is not rou-
tinely performed in primary healthcare. However, the
low prevalence of IBD in the primary healthcare setting
must be taken into account: the group of digestive disor-
ders does not belong to the main reasons for encounter
in primary healthcare. Scandinavian studies show fre-
quencies between 5% and 7%.26 27 Therefrom, IBS is
much more common in primary healthcare (popula-
tion-based prevalence of 10–15% in IBS compared with
0.2% in IBD). Therefore, a new tool has been developed
to narrow the patient collective in which calprotectin
testing may lead to the correct diagnosis of IBD in an
earlier stadium.
Hypothesis and goal
This study pursues two main aims A and B, which are
investigated independently:
A. Prospective validation and evaluation of sensitivity
and speciﬁcity of an 8-item IBD questionnaire
(CalproQuest; table 1) for (1) a positive calprotectin
test result ≥50 μg/g faeces and for (2) a positive cal-
protectin test result ≥50 μg/g faeces and positive IBD
diagnosis, respectively, in tertiary healthcare.
B. Prospective implementation of CalproQuest in primary
healthcare to investigate feasibility in daily practice.
METHODS AND ANALYSIS
Study design
The study is a prospective diagnostic trial. It consists of
two independent and consecutive parts A and B, con-
ducted by gastroenterologists (A) and general practi-
tioners (GPs) (B), respectively.
Patients included in part A of the study are referred
for endoscopic evaluation to gastroenterologists. Patients
included in part B of the study present at their GP
because of ongoing unspeciﬁc gastrointestinal symptoms
(abdominal pain, bloating, stool irregularities, diar-
rhoea) for at least 2 weeks.
The study design and procedure are summarised in
ﬁgure 1.
Inclusion and exclusion criteria
Patients will be eligible if they
▸ Are ≥18 years old (parts A, B)
▸ Are referred to their gastroenterologist for any endo-
scopic examination (part A)
▸ Visit their GP because of ongoing unspeciﬁc gastro-
intestinal symptoms (abdominal pain, bloating, stool
irregularities, diarrhoea) for at least 2 weeks (part B)
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▸ Underwent no earlier diagnostic procedures (endos-
copy) for the current episode (part B)
Patients are not eligible if they
▸ Are younger than 18 years (parts A, B)
▸ Have known further/other abdominal pathologies as,
for example, cancer (parts A, B)
▸ Had previous abdominal surgeries (part B)
▸ Have been treated with steroids (topical and/or oral)
and/or aminosalicylates within 30 days prior to inclu-
sion in this study (part B)
▸ Underwent endoscopic examination within 3 years
prior to screening (part B).
Primary and secondary outcomes
Primary outcomes:
1. Sensitivity and speciﬁcity of CalproQuest for a posi-
tive Calprotectin test result ≥50 μg/g faeces.
2. Sensitivity and speciﬁcity of CalproQuest for a posi-
tive Calprotectin test result ≥50 μg/g faeces and posi-
tive IBD diagnosis.
Feasibility of CalproQuest in a daily primary healthcare
practice.
Secondary outcomes:
A. Patient-reported diagnostic delay.
B. Patient-reported acceptance of stool sampling.
Procedure of the study
In brief, the study will be divided into two independent
parts A and B, conducted by gastroenterologists (A) and
GPs (B), respectively. Patient data will be encoded.
A. Investigation of the sensitivity and speciﬁcity of
CalproQuest for stool calprotectin levels ≥50 μg/g
faeces and for positive IBD diagnosis.
Patients referred to the gastroenterologist for endo-
scopic examination are subjected to CalproQuest and
calprotectin stool testing prior to endoscopy. At baseline
T0, patients will be subjected to CalproQuest.
Subsequently, at T1, faecal samples will be obtained to
measure calprotectin levels. The patients themselves will
perform collection of the faecal specimens. The faecal
specimens from outpatients will be shipped to the
laboratory at the University Hospital Zurich by mail.
After measurement, faecal samples will be disposed of
according to current guidelines. At T2, endoscopic
examination will be performed to obtain a diagnosis.
Eventually, patients diagnosed with IBD will be asked to
complete a questionnaire at T3 investigating the dur-
ation of ﬁrst onset of symptoms to IBD diagnosis (diag-
nostic delay).
B. Investigation of feasibility of CalproQuest in a daily
primary healthcare practice.
Patients with ongoing unspeciﬁc gastrointestinal symp-
toms (abdominal pain, bloating, stool irregularities, diar-
rhoea) for more than 2 weeks presenting at the GP will
be included in the study if all inclusion criteria are met
and informed patient consent is obtained.
At baseline (T0), patients will be subjected to
CalproQuest. Subsequently, at T1, faecal samples will be
obtained to measure calprotectin levels. The patients
themselves will perform collection of the faecal speci-
mens. The faecal specimens will be shipped to the
laboratory at the University Hospital Zurich by mail.
After measurement, faecal samples will be disposed of
according to current guidelines. According to the
current standard of care, it is recommended that
patients with calprotectin levels ≥50 μg/g be referred to
a gastroenterologist for endoscopic examination at T2;
results of the endoscopy are communicated back to the
GP. Patients will be asked at T3 to complete a question-
naire on acceptance of stool sampling, and physicians
will complete the questionnaire on feasibility of
CalproQuest in daily practice.
CalproQuest
CalproQuest is an eight-item IBD questionnaire consist-
ing of four main and four secondary questions speciﬁc
for IBD (see table 1). CalproQuest was prevalidated by
IBD experts through an international Delphi process.
CalproQuest is considered positive if ≥2 main criteria or
one main criterion and two secondary criteria are
answered positively.
Table 1 CalproQuest (8-item IBD questionnaire)
Type Criteria
Yes
(1)
No
(0) Comment
Major Does the patient suffer from abdominal pain at least 3 times a week for at least 4 weeks?
Does the patient suffer from diarrhoea (more than 3 bowel movements daily) for 7
consecutive days?
Does the patient have diarrhoea at night-time?/Does the patient awake from sleep
because of abdominal pain or diarrhoea?
Does the patient report a bloody stool?
Minor Does the patient report mucus in the stool for more than 4 weeks?
Does the patient report unwanted weight loss (5% of normal body weight over
6 months)?
Does the patient present with fever or report fever over the past 4 weeks (temperature
>38°C)?
Does the patient report fatigue over the past 4 weeks?
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We assume that a positive CalproQuest result may
predict calprotectin levels ≥50 μg/g. Calprotectin levels
above 50 μg/g are indicative of ongoing intestinal inﬂam-
mation and call for further endoscopic examination.
Faecal calprotectin
Faecal calprotectin levels will be measured at the
University Hospital Zurich by a novel ELISA-based calpro-
tectin test named EliA calprotectin (Thermo Scientiﬁc,
for product description see http://www.phadia.com/
PageFiles/29347/Product%20information%20EliA%20
Calprotectin.pdf).
Patient questionnaire on diagnostic delay
Three relevant time intervals of diagnostic delay will be
assessed in a patient questionnaire. The time intervals
are deﬁned as follows (ﬁgure 2):
1. Interval 1: Time from ﬁrst IBD-related symptoms to
ﬁrst consultation with the GP—this interval
represents the time span between the ﬁrst manifesta-
tions of IBD-related symptoms (patient reported)
and a consultation with the GP speciﬁcally due to
these IBD-related symptoms. The length of this
period is mainly dependent on the patient herself/
himself.
2. Interval 2: Time from the ﬁrst GP visit to referral to a
gastroenterologist—this represents the time span
between the IBD symptom-related consultation of the
GP and the time of referral to a gastroenterologist
for further examination. The length of this period is
mainly dependent on the treating GP.
3. Interval 3: Time from ﬁrst IBD symptoms to IBD diag-
nosis (intervals 1+2)—this interval is calculated by the
addition of intervals 1 and 2 and is deﬁned as diagnos-
tic delay. Diagnostic delay is deﬁned as the time span
(in weeks) from ﬁrst symptoms to IBD diagnosis.
The following items in the patient questionnaires are
assessed for the purpose of this study: “Before the IBD
diagnosis, how long did you experience symptoms that are
now attributed to IBD?”; “How long was the time interval
between ﬁrst symptoms and the ﬁrst visit to your GP?”;
“How long were you treated by your GP before referral to
a gastroenterologist?” and “What was the time span from
the ﬁrst physician visit (due to these complaints) until IBD
diagnosis was established?” Additionally, patients will
answer questions regarding smoking habits, intake of non-
steroidal anti-inﬂammatory drugs (NSAIDs) or oral contra-
ception at the time of diagnosis.
Physician questionnaire on feasibility and acceptance
of CalproQuest in primary healthcare
The goal of the feasibility questionnaire is to investigate
the feasibility and acceptance of CalproQuest in a daily
primary healthcare practice.
The questionnaire is based on an even-point Likert
scale consisting of seven items.
Figure 2 Intervals 1–3 in diagnostic delay (adapted from
Vavricka et al1). Interval 1: time from first IBD symptoms to
consultation with the general practitioner (GP). Interval 2: time
from GP visit to referral to a gastroenterologist. Interval 3: time
from first inflammatory bowel disease (IBD) symptoms to IBD
diagnosis (intervals 1+2).
Figure 1 Study design (GE, gastroenterologist; GP, general
practitioner, Neg, negative; Pos, positive).
4 Hasler S, et al. BMJ Open 2015;5:e007306. doi:10.1136/bmjopen-2014-007306
Open Access
Patient questionnaire on acceptance of stool sampling
The aim of the patient’s acceptance questionnaire is to
investigate patients’ physical and mental ability to
handle stool sampling at home.
The questionnaire is based on an even-point Likert
scale consisting of four items.
Administration of patient records
Physicians will be supplied with a master data list provid-
ing patient codes that can be assigned to the patient. All
documents containing patient data will carry the respect-
ive patient code assigned by the physician. encoded
documents will be sent to the Institute of Primary Care,
University of Zurich, Switzerland and stored for 10 years.
Only physicians have access to the patient codes. Data
entry is performed continuously at the Institute of
Primary Care, University of Zurich, and if data are
missing, a research assistant will investigate to obtain all
information as required.
Sample size calculation
The sample size in part A was calculated according to
Flahault et al.28 Assuming a 0.05 two-sided signiﬁcance
level, n=162 would have 90% power to detect a sensitivity
and speciﬁcity of 90% of CalproQuest for a calprotectin
level ≥50 μg/g faeces, or for a calprotectin level ≥50 μg/g
faeces and a positive IBD diagnosis. For the purpose of this
calculation, the expected sensitivity and speciﬁcity are 90%
with a lower acceptable limit of sensitivity of 70%. Assumed
prevalence of IBD within the sample is 20%. A p<0.05 is
considered statistically signiﬁcant. Eighty patients were
assumed to be necessary for the feasibility testing in part B.
Statistical data evaluation
We provide sensitivity and speciﬁcity calculation of
CalproQuest based on CIs (ﬁgure 3). For the other
primary or secondary outcomes, parametric or non-
parametric tests are used where appropriate.
Physician recruitment
Physician recruitment is ongoing to achieve the target
number of 162 patients; about 12–15 gastroenterologists
and IBD centres will be recruited in part A and 30 GPs
in part B. Country of recruitment: Switzerland.
Physicians will receive a ﬁnancial incentive.
Patient recruitment
Physicians from parts A and B are asked to approach
consecutively patients eligible for the trial. Patients do
not receive a ﬁnancial incentive, but the stool sampling
Figure 3 Sensitivity and
specificity calculation of
CalproQuest (FN, false negative;
FP, false positive; GE,
gastroenterologist; IBD,
inflammatory bowel disease;
NPV, Negative Predictive Value;
PPV, Positive Predictive Value;
TN, true negative; TP, true
positive).
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material and the faecal calprotectin test will be provided
for free.
Patient informed consent
Prior to study participation, patients receive written and
oral information about the consent and extent of the
planned study. In case of acceptance, they sign the
informed consent form. In case of study discontinuation,
all material will be destroyed or the patient will be asked
if he/she accepts that the existing material can be used
for the study.
Time frame of the study
Recruitment of gastroenterologists and GPs started in
October 2014. The recruitment time of the eligible
patients will be 12 months. Data analysis will be per-
formed 12 months after recruiting the last study centre
(part A: gastroenterologists, part B: GPs) or earlier, when
the target number of patients (part A: 162, part B: 80)
has been achieved.
Description of risks
In part A, an endoscopy will be performed; however,
these patients are already referred for endoscopic evalu-
ation to gastroenterologists. Therefore, an additional
risk is not expected.
Confidentiality
The patient names and all other conﬁdential informa-
tion fall under medical conﬁdentiality rules and are
treated according to appropriate Federal Data Security
Laws. The results of the patient questionnaires are not
accessible to the GPs. Questionnaires are directly mailed
to the study centre by the patient. All study-related data
and documents are stored on a protected central server
of the University of Zurich. Only direct members of the
internal study team can access the respective ﬁles.
Intermediate and ﬁnal reports are stored in the ofﬁce of
the Institute of Primary Care at the Zurich University
Hospital.
DISCUSSION
An early diagnosis of IBD is associated with a better
outcome. In primary healthcare, the prevalence of IBD
is much lower than in tertiary healthcare (a gastroenter-
ologist, or even in an IBD centre), where patients are
already preselected by GPs. The emphasis in tertiary
healthcare is usually on ‘ruling in’: increasing the prob-
ability of IBD to carry out more expensive, time-
consuming and invasive procedures; establish a ﬁrm
diagnosis; and start appropriate treatment. At the ter-
tiary healthcare level, a diagnostic test with a high posi-
tive likelihood ratio is preferred. In primary healthcare,
the emphasis is on ‘ruling out’: lowering the probability
of the target disease to provide reassurance, or to adopt
a ‘watchful waiting’ strategy. In these instances, tests with
a low negative likelihood ratio are preferred.6 By
increasing the sensitivity and speciﬁcity of the faecal cal-
protectin test by the CalproQuest questionnaire, which is
feasible in primary healthcare, we could provide a
simple, convenient tool to lower the diagnostic delay in
patients with IBD.
Limitations and strength
No conclusions can be made about the sensitivity or spe-
ciﬁcity of the test in primary healthcare, as the sample
size is too low (n=80 patients in part B). From other
ongoing studies with diseases, which are more prevalent,
we know that recruitment of patients in primary health-
care is very difﬁcult since participation is based on GPs’
free choice and implementation of research in the daily
routine of a general practice is time-consuming. We
therefore chose the design of two different parts in two
different settings. If CalproQuest is validated in tertiary
healthcare, further studies will be needed to evaluate
the accuracy of the test in primary healthcare.
In primary healthcare (part B), patients present them-
selves with symptoms, not with a presumed diagnosis. In
tertiary healthcare (part A), patients might already have
had the ﬁrst endoscopic investigation as well as treatment
and are referred because they do not respond to the estab-
lished therapy or because of unclearness of the diagnosis.
As different habits or conditions interfere with the value of
calprotectin, the exclusion criteria in some studies are
strict (regular intake of aspirin and/or NSAIDs, urinary
incontinence as faecal calprotectin is not waterproof,
infectious enterocolitis, colorectal cancer, etc).19 As we
want to determine the feasibility in a primary healthcare
population, we do not exclude patients presenting with
these conditions, because we want to represent the ‘real
life’ in the daily routine of a GP.
TRIAL STATUS
Patient recruitment had started in November 2014.
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